CVL237 tablets

DRUG3 trials

Sponsors

Convalife (Shanghai) Co., Ltd.

Conditions

Advanced Solid TumorsLocally Advanced or Metastatic Solid TumorsPI3K and P110delta Hyperactivation SyndromePTEN Loss or Low Expression

Phase 2

CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency

Not yet recruitingNCT06183736

Convalife (Shanghai) Co., Ltd.Advanced Solid Tumors

Start: 2023-12-20End: 2027-06-30Target: 98Updated: 2023-12-27

CVL237 Tablets for APDS/PASLI

Not yet recruitingNCT06293716

Convalife (Shanghai) Co., Ltd.PI3K and P110delta Hyperactivation Syndrome

Start: 2024-03-30End: 2026-03-30Target: 35Updated: 2024-03-05

A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

Not yet recruitingNCT07446049

Convalife (Shanghai) Co., Ltd.Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression

Start: 2026-05-01End: 2028-04-08Target: 180Updated: 2026-03-03